Physician profile
Rod E Robinson
NPI 1508946328
$2,776.94
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $763 · 2021: $105 · 2023: $96.75 · 2024: $14.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $433.21 | 2019-2021 | |
| Glaxosmithkline, LLC. | $402.35 | 2019-2023 | Shingrix |
| Novo Nordisk INC | $244.78 | 2019-2020 | |
| Pfizer INC. | $239.54 | 2019-2020 | |
| Lilly USA, LLC | $211.99 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $150.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.12 | 2019-2020 | |
| Allergan, INC. | $119.11 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.77 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $79.62 | 2019-2020 | |
| Amarin Pharma, INC. | $76.33 | 2019-2020 | |
| Orexo US, INC. | $70.97 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $64.37 | 2019 | |
| Ironshore Pharmaceuticals INC. | $50.19 | 2019 | |
| Amgen INC. | $48.91 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.18 | 2019-2020 | |
| Eisai INC. | $38.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.57 | 2019 | |
| Abbvie INC. | $17.00 | 2019 | |
| Sanofi Pasteur INC. | $15.26 | 2019 | |
| Medline Industries Lp | $14.90 | 2024 | |
| Adlon Therapeutics L.P. | $14.13 | 2020 | |
| Antares Pharma, INC. | $13.85 | 2019 | |
| Upsher-Smith Laboratories LLC | $13.71 | 2020 | |
| Astellas Pharma US INC | $13.68 | 2019 | |
| Mdd US Operations, LLC | $11.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rod Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.